[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100620719":3},{"organization":4,"outcomesModule":7,"designInfo":21,"detailedDescription":24,"studyPopulation":25,"armGroups":20,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":37,"responsibleParty":50,"collaborators":20,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":54,"sex":60,"minAge":61,"maxAge":20,"enrollmentInfo":62,"targetDuration":20,"studyType":65,"phases":20,"briefSummary":66,"conditions":67,"keywords":69,"overallStatus":40,"whyStopped":20,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"AstraZeneca","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":20},[9],{"measure":10,"description":11,"timeFrame":12},"Uncontrolled blood pressure","Proportion of patients with uncontrolled blood pressure (BP ≥ 140\u002F90 mmHg) who did not receive treatment intensification within 3 months of a recorded elevated BP.","through study completion, an average of 1 year",[14,17],{"measure":15,"description":16,"timeFrame":12},"Antihypertensive treatment","Proportions receiving monotherapy vs. combination therapy; distribution by pharmacologic class.",{"measure":18,"description":19,"timeFrame":12},"Risk stratification","Likelihood of treatment escalation stratified by low\u002Fmoderate vs. high\u002Fvery high CV risk.",null,{"allocation":20,"interventionModel":20,"interventionModelDescription":20,"primaryPurpose":20,"observationalModel":22,"timePerspective":23,"maskingInfo":20},"COHORT","RETROSPECTIVE","This is a retrospective observational cohort study based on secondary use of routinely collected electronic health data. The design was selected to enable population-level characterisation of treatment patterns and clinical inertia (both diagnostic and therapeutic) in the management of hypertension across diverse settings in Brazil's public primary care system (SUS).\n\nThe retrospective cohort design allows for efficient use of existing clinical data to evaluate real-world practice against national guideline recommendations. The primary outcomes relate to treatment decisions and delays rather than interventional effects; therefore, an observational design is methodologically appropriate and ethically preferable.\n\nThe study will be conducted across 05 Brazilian municipalities participating in the epHealth Primary Care Solutions platform. These municipalities span multiple regions and reflect heterogeneity in socio-demographic context, healthcare infrastructure, and epidemiological profiles.","Adults registered in the e-SUS PEC system who had encounters with primary healthcare services within the study period and had blood pressure measurements recorded. We will assess data from the entire population of approximately 05 muncipalities (comprising between 100.000 and 250.000 inhabitants). The municipalities will be seleceted from a pre-screened list of 20 cities located within all Brazilian regions.",[27],{"name":28,"affiliation":29,"role":30},"Julia Machline Carrion, Medical","EpHealth Soluções em Tecnologia da Informação Ltda","PRINCIPAL_INVESTIGATOR",[32],{"name":33,"role":34,"phone":35,"phoneExt":20,"email":36},"AstraZeneca Clinical Study Information Center","CONTACT","1-877-240-9479","information.center@astrazeneca.com",[38],{"facility":39,"status":40,"city":41,"state":20,"zip":20,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":20},"Research Site","RECRUITING","Florianópolis","Brazil","BR",{"type":45,"coordinates":46},"Point",[47,48],-48.54917,-27.59667,{"lat":48,"lon":47},{"type":51,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100620719","observational-study-that-will-evaluate-treatment-patterns-in-the-management-of-hypertension-in-the-public-primary-care-system-100620719",false,"NCT07361276","Observational Study That Will Evaluate Treatment Patterns in the Management of Hypertension in the Public Primary Care System","Clinical Landscape of Epidemiology and Assessment of Results in Hypertension","CLEAR-HTN","Inclusion Criteria:\n\n* Age ≥18 years at the time of Hypertension diagnosis\n* Hypertension diagnosis as retrieved from registered ICD codes or CIAP Codes (primary care codes) in the EMR , OR At least two blood pressure measurements ≥140\u002F90 mmHg during the study period. The blood measurements should be consecutive and obtained within a 30 days period.\n* Continuous follow-up in the same municipality for at least 6 months after index measurement.\n* Availability of structured EMR data including clinical encounters, diagnoses, and prescriptions\n\nExclusion Criteria:\n\n\\- Patients with incomplete data or not traceable in the registration systems","ALL","18 Years",{"count":63,"type":64},15000,"ESTIMATED","OBSERVATIONAL","This is a retrospective observational cohort study based on secondary use of routinely collected electronic health data. The design was selected to enable population-level characterisation of treatment patterns and clinical inertia (both diagnostic and therapeutic) in the management of hypertension across diverse settings in Brazil's public primary care system (SUS).",[68],"Hypertension",[70],"Blood Pressure, High","2026-07-23",{"date":73,"type":74},"2026-07-24","ACTUAL",{"date":76,"type":74},"2026-03-31",{"date":78,"type":64},"2026-07-31",{"name":5,"class":6},1]